BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24138307)

  • 1. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
    García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
    Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
    Morita Y; Shimada T; Yamaguchi T; Rai S; Hirase C; Emoto M; Serizawa K; Taniguchi Y; Ojima M; Tatsumi Y; Ashida T; Matsumura I
    Int J Hematol; 2011 Dec; 94(6):583-4. PubMed ID: 22127558
    [No Abstract]   [Full Text] [Related]  

  • 4. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
    Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
    Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenalidomide--the phoenix rises.
    List AF
    N Engl J Med; 2007 Nov; 357(21):2183-6. PubMed ID: 18032768
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
    Brioli A; Melchor L; Titley I; Vijayaraghavan G; Stephens C; Zeisig A; Pawlyn C; Cavo M; Morilla R; Davies FE; Morgan GJ
    Leuk Lymphoma; 2014 Nov; 55(11):2665-8. PubMed ID: 24660850
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
    Ying L; YinHui T; Yunliang Z; Sun H
    Oncotarget; 2017 Jul; 8(28):46593-46600. PubMed ID: 28423741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe hypocalcemia due to lenalidomide.
    Kong S; Collet P; Marotte H; Thomas T
    Joint Bone Spine; 2015 Oct; 82(5):380-1. PubMed ID: 25726251
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
    Barley K; He W; Agarwal S; Jagannath S; Chari A
    Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
    Singh A; Gajra A
    Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
    Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
    Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on second primary malignancies in multiple myeloma: a focused review.
    Landgren O; Mailankody S
    Leukemia; 2014 Jul; 28(7):1423-6. PubMed ID: 24418993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
    Milrod CJ; Blevins F; Hughes D; Lerner A; Sarosiek S; Sanchorawala V; Sloan JM
    Blood; 2021 May; 137(21):2987-2989. PubMed ID: 33728443
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential new risks of lenalidomide.
    Gertz MA; Buadi FK
    Leuk Lymphoma; 2014 Sep; 55(9):1962-3. PubMed ID: 24304420
    [No Abstract]   [Full Text] [Related]  

  • 18. Diffuse alveolar hemorrhage associated with lenalidomide.
    Sakai M; Kubota T; Kuwayama Y; Ikezoe T; Yokoyama A
    Int J Hematol; 2011 Jun; 93(6):830-831. PubMed ID: 21573890
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.